- Home
- Research
- CoMH Research & Innovation eBulletin
- Research Workshops
- CoMH Research and Innovation Committee
- Inclusion Health Research Group (IHRG)
- Researcher Spotlight Series
- APC Microbiome Institute
- INFANT
- ASSERT
- Biosciences Imaging Centre
- Centre for Gerontology & Rehabilitation
- Centre for Research in Vascular Biology
- Cork NeuroScience Centre
- Cancer Research @UCC
- HRB Clinical Research Facility Cork
- National Perinatal Epidemiology Centre
- Oral Health Services Research Centre
- ENTO (Ear, Nose, Throat and Oral Research Unit)
- News
- People
- Programmes
- Hospital Partners
- Community Partners
- Jennings Gallery
- Graduate Studies
- Programmes for International (Non-EU) Students
- Interprofessional Learning (IPL)
- ASSERT
- iEd Hub
- Inaugural Professorial Lecture Series
- Philanthropic Lectures
- UCC Academic Health Sciences
- Continuing Professional Development
News
UCC-led EU training network ‘PEARRL’ kicks off’
PEARRL (Pharmaceutical Education And Research with Regulatory Links) is a European Training Network (ETN) for innovative drug formulation strategies and biopharmaceutics tools with regulatory application.
The programme is funded (€ 4 million) under the European Union’s Horizon 2020 research and innovation programme (Marie Sklodowska-Curie actions) and is co-ordinated by Dr. Brendan Griffin from the School of Pharmacy, University College Cork (UCC).
The PEARRL project brings together 18 leading European institutions, including Pharma industry (9), academia (5) and regulatory agency (4) partners in a multi-sectorial team to deliver a unique research and training programme. 15 Early Stage Researchers have been recruited in PEARRL, to focus their research endeavours on developing innovative drug development strategies to enable accelerated approval, thus facilitating earlier patient access to new medicines.
PEARRL Research Objectives
The main research objectives of PEARRL are to develop novel bio-enabling formulations (“better drugs”), new biopharmaceutics tools and predictive in silico methods to forecast drug levels in humans (“streamlined development”), which together will serve as communication bridgers between research and regulatory science (“accelerated approval”), thus improving the efficiency and cost-competitiveness of pharmaceutical R&D. The key impact will be that new medicines will be brought to the market faster, and at reduced cost, therein facilitating earlier access of patients to breakthrough therapies
PEARRL engages the Pharma industry through our partners Janssen, Merck, Pharmathen, Sirius and Biorelevant.com as well as facilitating collaboration with and among partner regulatory organizations, EMA, HRPA, BfArM and MHRA, and further strengthening Europe`s scientific excellence in academia at our partner universities, namely University College Cork, Johann Wolfgang Goethe University, Frankfurt, National and Kapodistrian University of Athens, University of Applied Sciences & Arts Northwestern Switzerland, and University of Bath.
PEARRL Facts and Figures
PEARRL is a research project, co-funded by the European Union
- Involves 8 beneficiaries and 10 partner organisations (5 academic, 8 industry, 4 regulatory agencies, 1 management)
- Started on 1 May 2016 , Kick off meeting 31 October 2016, will end on 30 April 2020
- Budget: 3.9 million euro
- Website: www.pearrl.eu